(Lung Cancer) Efficacy of Opdivo + Yervoy as First-Line Treatment?

On July 24, 2019, a global biopharmaceutical company announced the "Efficacy and Safety Results of Combined Anti-PD-1 Antibody Opdivo (nivolumab) Plus Anti-CTLA-4 Antibody Yervoy (ipilimumab) as First-Line Treatment in Non-Small Cell Lung Cancer Patients with PD-L1 Expression of 1% or More in the CheckMate-227 (Part 1a) Phase III Clinical Trial."

The CheckMate-227 trial (Part 1a) randomly assigned non-small cell lung cancer patients with PD-L1 expression of 1% or more to either the Opdivo + Yervoy group (every 2 weeks: Opdivo 3mg/kg + every 6 weeks: Yervoy 1mg/kg) or the chemotherapy group, comparing them in a Phase III clinical trial with overall survival as the primary endpoint.

The trial results showed that the Opdivo + Yervoy group demonstrated a significant improvement in the primary endpoint of overall survival compared to the chemotherapy group, achieving the primary endpoint. Additionally, PD-L1-negative non-small cell lung cancer patients receiving first-line Opdivo + Yervoy treatment also showed favorable responses. Regarding safety, the adverse events observed in this trial were consistent with data from other current clinical trials, and no new adverse events occurred.

Based on the CheckMate-227 (Part 1a) trial results, Fouad Namouni concluded: "CheckMate-227 is the first large-scale trial to demonstrate the efficacy of checkpoint inhibitors as first-line treatment in non-small cell lung cancer patients."

Source: Bristol-Myers Squibb

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Cancer Information

• Lung cancer